Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

Exclusion Criteria

• •Prior participation in an afatinib clinical study, even if not assigned to afatinib treatment
• •Prior systemic therapy for metastatic or recurrent NSCLC.
• •Concurrent investigational therapy or investigational therapy within 4 weeks of start of afatinib therapy
• •Radiotherapy within 4 weeks prior to start of study treatment, except as follows:
• •* Palliative radiation to target organs other than chest may be allowed up to 2 weeks prior to study treatment, or
• •* Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling.
• •* Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study
• •* Systemic chemotherapy, biological therapy, immunotherapy or investigational agents within 5 half-life of the drug or within four weeks prior to the start of afatinib treatment (if the half-life of the drug is unknown).
• •Men, capable of fathering a child, who are unwilling to use adequate contraception prior to study entry, for the duration of study participation, and for at least 28 days after treatment has ended.